Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan (LixiRam)
Phase 4
Completed
- Conditions
- Health Condition 1: null- Type 2 Diabetes Mellitus PatientsHealth Condition 2: E119- Type 2 diabetes mellitus without complications
- Registration Number
- CTRI/2017/03/007979
- Lead Sponsor
- SanofiSynthelabo India Private Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 150
Inclusion Criteria
Patients with T2DM,
For complete list of inclusion criteria, please contact sponsor
Exclusion Criteria
HbA1c at screening visit < 7.5% or > 10%
For complete list of exclusion criteria, please contact sponsor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method